• PK/PD of Gamithromycin in Bovine Respiratory Disease: A PELF

  2026-05-01

  This study rigorously characterizes the pharmacokinetics and pharmacodynamics of Gamithromycin in naturally occurring bovine respiratory disease, revealing that drug exposure in pulmonary epithelial lining fluid (PELF) is a key predictor of treatment success against Pasteurella multocida. The findings support the use of AUC/MIC indices in PELF for optimizing dosing strategies in veterinary respiratory research.

• Sunitinib (SKU B1045): Robust RTK Inhibition in RCC Assays

  2026-05-01

  This article provides practical, evidence-based guidance for biomedical researchers using Sunitinib (SKU B1045) to address challenges in cell viability, proliferation, and cytotoxicity assays. Drawing on recent literature and validated workflows, it highlights how APExBIO’s Sunitinib enhances experimental reproducibility and data interpretation in renal cell carcinoma research.

• Methyl-β-cyclodextrin: Practical Guidance for Membrane Studi

  2026-04-30

  Methyl-β-cyclodextrin is a high-purity cyclic oligosaccharide used to extract cholesterol and other lipids from cellular membranes, supporting studies in membrane dynamics and lipid raft disruption. It is intended for laboratory-based research only, not for diagnostic or clinical use.

• Thrombin B Chain Fragment: Unveiling Microenvironmental Cont

  2026-04-30

  Explore how the Thrombin B Chain Fragment, a trypsin-like serine protease, mediates not just fibrinogen to fibrin conversion but also shapes endothelial dynamics in the fibrin matrix. This article reveals new microenvironment insights and practical assay guidance, setting it apart from existing resources.

• Lamotrigine: Applied Workflows for Sodium Channel Blockade

  2026-04-29

  Lamotrigine is a gold-standard sodium channel blocker and 5-HT inhibitor, enabling reproducible CNS and cardiac research workflows. Explore protocol optimizations, troubleshooting strategies, and data-driven guidance to maximize reliability and translational value.

• Necrostatin-1: Applied RIP1 Kinase Inhibition in Necroptosis

  2026-04-29

  Necrostatin-1 empowers researchers with precision inhibition of RIP1 kinase, enabling robust necroptosis assays and translational modeling of inflammatory injury. This article unpacks practical workflows, troubleshooting strategies, and cutting-edge insights for maximizing assay reproducibility and biological relevance.

• LDH Cytotoxicity Assay Kit: Precision Cell Damage Measuremen

  2026-04-28

  The LDH Cytotoxicity Assay Kit from APExBIO provides a non-radioactive, robust, and sensitive platform for cell cytotoxicity measurement. Its proven reliability in nanocomposite biocompatibility, cancer research, and apoptosis detection positions it as a gold standard for quantitative cell damage analysis across experimental domains.

• Tofacitinib Citrate: Navigating JAK3 Selectivity in Translat

  2026-04-28

  This thought-leadership article explores the mechanistic foundations, comparative insights, and translational strategies for deploying tofacitinib citrate (CP-690550 citrate) in immune regulation and inflammatory disorder research. Drawing on recent comparative endothelial studies and real-world protocol benchmarks, we dissect how JAK3 selectivity, experimental context, and emerging cardiovascular findings should inform the design and interpretation of preclinical and translational workflows.

• CAFs-Derived Lactate Drives Oxaliplatin Resistance via ANTXR

  2026-04-27

  This study uncovers how lactate released by cancer-associated fibroblasts (CAFs) promotes oxaliplatin resistance in colorectal cancer (CRC) by inducing ANTXR1 lactylation, which enhances cancer stemness and activates the RhoC/ROCK1/SMAD5 pathway. The findings highlight the tumor microenvironment’s metabolic crosstalk as a critical driver of chemoresistance and suggest new avenues for improving therapy efficacy.

• BIBR 1532: Precision Telomerase Inhibition in Cancer Researc

  2026-04-27

  Explore how BIBR 1532, a selective telomerase inhibitor, enables next-generation cancer research through targeted hTERT inhibition and advanced apoptosis pathways. This in-depth analysis reveals unique mechanistic insights and practical assay strategies.

• Amikacin (BAY416651): Applied Protocols in Antibiotic Resist

  2026-04-26

  Amikacin (BAY416651) is revolutionizing antibiotic resistance research by offering robust activity where other aminoglycosides fail. This article distills advanced experimental workflows, troubleshooting, and unique delivery strategies—especially for targeting drug-resistant bacteria and granulomatous infections.

• Necrosulfonamide (NSA): Specific MLKL Inhibitor for Necropto

  2026-04-25

  Necrosulfonamide (NSA) is a potent, selective inhibitor of MLKL-mediated necroptosis, widely used in cell death pathway research. NSA blocks necroptosis without affecting apoptosis, enabling precise study of regulated necrosis. Its specificity and nanomolar efficacy make it a benchmark compound for dissecting necroptosis mechanisms in cancer and neurodegenerative disease models.

• DiscoveryProbe Protease Inhibitor Library: Optimizing HTS As

  2026-04-24

  The DiscoveryProbe™ Protease Inhibitor Library empowers high-throughput, pathway-centric research across oncology, infectious disease, and apoptosis studies. This article delivers actionable workflows, protocol parameters, and expert troubleshooting—bridging validated evidence with innovative screening strategies.

• CKI 7 Dihydrochloride: Optimize Casein Kinase 1 Inhibition W

  2026-04-24

  CKI 7 dihydrochloride empowers researchers to selectively inhibit Casein kinase 1, streamlining Wnt signaling and circadian biology assays. This guide details experimental workflows and troubleshooting strategies that enhance reproducibility in cancer and neurobiology research.

• ECM1 Epitope LA Vaccine Primes CD8+ T and NK Cells for Tumor

  2026-04-23

  Yu et al. (2021) identify a novel HLA-A2.1-restricted ECM1-derived epitope, LA, that primes dendritic cells to cross-activate both CD8+ T cells and NK cells, resulting in potent antitumor immunity. This work introduces a dual-activation tumor vaccine strategy, with significant implications for cancer immunotherapy design and mechanistic study of adaptive and innate immune crosstalk.

16309 records 1/1088 page Next 12345 下5页 Last page